labetalol has been researched along with Body Weight in 16 studies
Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sixty-one patients (41 men, 20 women) aged 29-73 years, with moderate to severe hypertension, were enrolled in a multicentre study to compare the efficacy, safety, and tolerability of dilevalol (D) and captopril (C)." | 9.06 | Double-blind study of dilevalol and captopril, both in combination with hydrochlorothiazide, in patients with moderate to severe hypertension. ( Fraser, I; Howes, L; Kincaid-Smith, PS; Louis, W; MacDonald, G; Matthews, PG; McGrath, BP; Rallings, M; Scheinkestel, C; Whitworth, JA, 1990) |
| "Labetalol is frequently prescribed for the treatment of hypertension during pregnancy; however, the influence of pregnancy on labetalol pharmacokinetics is uncertain, with inconsistent findings reported by previous studies." | 7.80 | Influence of gestational age and body weight on the pharmacokinetics of labetalol in pregnancy. ( Deyo, K; Endres, L; Fischer, JH; Fischer, PA; Geller, S; Hardman, J; Jenkins, TM; Jeong, H; Kilpatrick, SJ; Rodvold, KA; Sarto, GE, 2014) |
| "We investigated the effects of the beta1-beta2-alpha1-blocker, labetalol, in the congestive heart failure (CHF) model induced by aortic constriction in the guinea pig." | 7.71 | Early anti-remodeling effect of labetalol in the congestive heart failure model induced by aortic constriction in the guinea pig. ( Bellissant, E; Goineau, S; Guillo, P; Pape, D; Ramée, MP, 2002) |
| "Arterial blood pressure and plasma catecholamines, renin activity and aldosterone concentration in 12 patients with severe essential hypertension were studied before and after combined alpha- and beta- adrenoceptor blockade induced by oral labetalol treatment for 2 months." | 7.66 | Plasma catecholamines, renin and aldosterone during combined alpha- and beta- adrenoceptor blockade in patients with severe arterial hypertension. ( Christensen, NJ; Kornerup, HJ; Pedersen, A; Pedersen, EB; Pedersen, G, 1980) |
| "Arterial blood pressure and plasma catecholamines, renin activity and aldosterone concentration in 12 patients with severe essential hypertension were studied before and after combined alpha- and beta-adrenergic receptor blockage induced by oral labetalol treatment for 2 months." | 7.66 | Effect of oral labetalol on plasma catecholamines, renin and aldosterone in patients with severe arterial hypertension. ( Christensen, NJ; Kornerup, HJ; Pedersen, A; Pedersen, EB; Pedersen, G, 1979) |
| "Sixty-one patients (41 men, 20 women) aged 29-73 years, with moderate to severe hypertension, were enrolled in a multicentre study to compare the efficacy, safety, and tolerability of dilevalol (D) and captopril (C)." | 5.06 | Double-blind study of dilevalol and captopril, both in combination with hydrochlorothiazide, in patients with moderate to severe hypertension. ( Fraser, I; Howes, L; Kincaid-Smith, PS; Louis, W; MacDonald, G; Matthews, PG; McGrath, BP; Rallings, M; Scheinkestel, C; Whitworth, JA, 1990) |
| "Labetalol is frequently prescribed for the treatment of hypertension during pregnancy; however, the influence of pregnancy on labetalol pharmacokinetics is uncertain, with inconsistent findings reported by previous studies." | 3.80 | Influence of gestational age and body weight on the pharmacokinetics of labetalol in pregnancy. ( Deyo, K; Endres, L; Fischer, JH; Fischer, PA; Geller, S; Hardman, J; Jenkins, TM; Jeong, H; Kilpatrick, SJ; Rodvold, KA; Sarto, GE, 2014) |
| "We investigated the effects of the beta1-beta2-alpha1-blocker, labetalol, in the congestive heart failure (CHF) model induced by aortic constriction in the guinea pig." | 3.71 | Early anti-remodeling effect of labetalol in the congestive heart failure model induced by aortic constriction in the guinea pig. ( Bellissant, E; Goineau, S; Guillo, P; Pape, D; Ramée, MP, 2002) |
| "Arterial blood pressure and plasma catecholamines, renin activity and aldosterone concentration in 12 patients with severe essential hypertension were studied before and after combined alpha- and beta- adrenoceptor blockade induced by oral labetalol treatment for 2 months." | 3.66 | Plasma catecholamines, renin and aldosterone during combined alpha- and beta- adrenoceptor blockade in patients with severe arterial hypertension. ( Christensen, NJ; Kornerup, HJ; Pedersen, A; Pedersen, EB; Pedersen, G, 1980) |
| "Arterial blood pressure and plasma catecholamines, renin activity and aldosterone concentration in 12 patients with severe essential hypertension were studied before and after combined alpha- and beta-adrenergic receptor blockage induced by oral labetalol treatment for 2 months." | 3.66 | Effect of oral labetalol on plasma catecholamines, renin and aldosterone in patients with severe arterial hypertension. ( Christensen, NJ; Kornerup, HJ; Pedersen, A; Pedersen, EB; Pedersen, G, 1979) |
| " In all the drug-treated groups, increase in salivation was observed from immediately to 15 minutes after dosing through the treatment period." | 1.26 | [On the subacute toxicity of labetalol (AH5158): a combined alpha-and beta-adrenoceptor blocking agent (author's transl)]. ( Fujiwara, S; Shimpo, K; Tanabe, T; Togashi, H; Yokoi, Y, 1980) |
| " In all the drug-treated groups, increase in salivation was observed from immediately after to 15 minutes after dosing through treatment period." | 1.26 | [On the chronic toxicity of labetalol (AH-5158); a combined alpha-and beta-adrenoceptor-blocking agent (author's transl)]. ( Fujiwara, S; Shimpo, K; Tanabe, T; Togashi, H; Yokoi, Y, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (56.25) | 18.7374 |
| 1990's | 5 (31.25) | 18.2507 |
| 2000's | 1 (6.25) | 29.6817 |
| 2010's | 1 (6.25) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fischer, JH | 1 |
| Sarto, GE | 1 |
| Hardman, J | 1 |
| Endres, L | 1 |
| Jenkins, TM | 1 |
| Kilpatrick, SJ | 1 |
| Jeong, H | 1 |
| Geller, S | 1 |
| Deyo, K | 1 |
| Fischer, PA | 1 |
| Rodvold, KA | 1 |
| Hunyor, SN | 1 |
| Bauer, GE | 1 |
| Ross, M | 1 |
| Larkin, H | 1 |
| Kornerup, HJ | 3 |
| Pedersen, EB | 3 |
| Pedersen, A | 3 |
| Pedersen, G | 3 |
| Christensen, NJ | 3 |
| Shimpo, K | 2 |
| Yokoi, Y | 2 |
| Fujiwara, S | 2 |
| Togashi, H | 2 |
| Tanabe, T | 2 |
| Pape, D | 1 |
| Goineau, S | 1 |
| Guillo, P | 1 |
| Ramée, MP | 1 |
| Bellissant, E | 1 |
| Weidmann, P | 1 |
| De Chătel, R | 1 |
| Ziegler, WH | 1 |
| Flammer, J | 1 |
| Reubi, F | 1 |
| Prichard, BN | 1 |
| Boakes, AJ | 1 |
| Hernández, R | 1 |
| Bolli, P | 1 |
| Waal-Manning, J | 1 |
| Wood, AJ | 1 |
| Simpson, FO | 1 |
| Erdtsieck-Ernste, EB | 1 |
| Feenstra, MG | 1 |
| Botterblom, MH | 1 |
| De Barrios, J | 1 |
| Boer, GJ | 1 |
| Selan, F | 1 |
| McCullough, CB | 1 |
| Black, HE | 1 |
| McGrath, BP | 1 |
| Matthews, PG | 1 |
| Louis, W | 1 |
| Howes, L | 1 |
| Whitworth, JA | 1 |
| Kincaid-Smith, PS | 1 |
| Fraser, I | 1 |
| Scheinkestel, C | 1 |
| MacDonald, G | 1 |
| Rallings, M | 1 |
| Gonzalez, ER | 1 |
| Peterson, MA | 1 |
| Racht, EM | 1 |
| Ornato, JP | 1 |
| Due, DL | 1 |
| Abate, MA | 1 |
| Neely, JL | 1 |
| Layne, RD | 1 |
| D'Alessandri, R | 1 |
7 trials available for labetalol and Body Weight
| Article | Year |
|---|---|
Labetalol and propranolol in mild hypertensives: comparison of blood pressure and plasma volume effects.
Topics: Adult; Aged; Blood Pressure; Body Weight; Drug Therapy, Combination; Ethanolamines; Female; Humans; | 1980 |
Labetalol in the treatment of severe essential hypertension: relationship between arterial blood pressure, plasma catecholamines, plasma renin activity, plasma aldosterone and body weight.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Aldosterone; Blood Pressure; | 1979 |
Alpha and beta adrenergic blockade with orally administered labetalol in hypertension. Studies on blood volume, plasma renin and aldosterone and catecholamine excretion.
Topics: Adult; Aged; Aldosterone; Blood Pressure; Blood Volume; Body Weight; Chlorthalidone; Clinical Trials | 1978 |
Experience with labetalol in hypertension.
Topics: Adult; Aged; Blood Pressure; Body Weight; Clinical Trials as Topic; Diuretics; Drug Evaluation; Drug | 1976 |
Double-blind study of dilevalol and captopril, both in combination with hydrochlorothiazide, in patients with moderate to severe hypertension.
Topics: Adult; Aged; Blood Pressure; Body Weight; Captopril; Double-Blind Method; Drug Therapy, Combination; | 1990 |
Dose-response evaluation of oral labetalol in patients presenting to the emergency department with accelerated hypertension.
Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Blood Pressure; Body Weight; Dose-Response | 1991 |
Interaction of indomethacin and sulindac with labetalol.
Topics: Adult; Aged; Analysis of Variance; Blood Pressure; Body Weight; Chlorides; Drug Interactions; Humans | 1991 |
9 other studies available for labetalol and Body Weight
| Article | Year |
|---|---|
Influence of gestational age and body weight on the pharmacokinetics of labetalol in pregnancy.
Topics: Adolescent; Adult; Antihypertensive Agents; Body Weight; Dose-Response Relationship, Drug; Female; G | 2014 |
Plasma catecholamines, renin and aldosterone during combined alpha- and beta- adrenoceptor blockade in patients with severe arterial hypertension.
Topics: Adult; Aged; Aldosterone; Body Weight; Epinephrine; Ethanolamines; Female; Humans; Hypertension; Lab | 1980 |
[On the subacute toxicity of labetalol (AH5158): a combined alpha-and beta-adrenoceptor blocking agent (author's transl)].
Topics: Animals; Body Weight; Drinking; Ethanolamines; Female; Kidney; Labetalol; Liver; Male; Muscles; Pota | 1980 |
[On the chronic toxicity of labetalol (AH-5158); a combined alpha-and beta-adrenoceptor-blocking agent (author's transl)].
Topics: Animals; Body Weight; Drinking; Eating; Ethanolamines; Female; Labetalol; Male; Organ Size; Rats | 1981 |
Early anti-remodeling effect of labetalol in the congestive heart failure model induced by aortic constriction in the guinea pig.
Topics: Adrenergic beta-Antagonists; Animals; Aorta; Aortic Valve Stenosis; Body Weight; Disease Models, Ani | 2002 |
Effect of oral labetalol on plasma catecholamines, renin and aldosterone in patients with severe arterial hypertension.
Topics: Adult; Aged; Aldosterone; Blood Pressure; Body Weight; Catecholamines; Epinephrine; Ethanolamines; F | 1979 |
Long-term treatment of hypertension with labetalol.
Topics: Adult; Aged; Blood Cell Count; Blood Pressure; Body Weight; Drug Tolerance; Ethanolamines; Female; H | 1979 |
Changes in adrenoceptors and monoamine metabolism in neonatal and adult rat brain after postnatal exposure to the antihypertensive labetalol.
Topics: Animals; Animals, Newborn; Biogenic Amines; Body Weight; Brain; Labetalol; Organ Size; Propranolol; | 1992 |
Preclinical safety evaluation of dilevalol (SCH 19927), an antihypertensive agent, in the rat.
Topics: Animals; Antihypertensive Agents; Blood Chemical Analysis; Body Weight; Drug Evaluation, Preclinical | 1992 |